Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr.Reddy's Laboratories Ltd    DRREDDY   INE089A01023

End-of-day quote. End-of-day quote  - 08/24
3043.55 INR   +1.04%
08/04 Dr Reddy's completes acquisition of 8 ANDAs from Teva Pharma
08/03 DR REDDY LABORA : . Reddy’s Completes Acquisition of Product P..
08/02 CIPLA : appoints Kedar Upadhye as Global Chief Financial Officer
News SummaryMost relevantAll newsSector news 

Dr. Reddy's Laboratories Limited : Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection

share with twitter share with LinkedIn share with facebook
share via e-mail
03/05/2013 | 10:15am CEST

Hyderabad, India, March 05, 2013

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa® (zoledronic acid) 4 mg/5 mL Injection in the US market on March 4, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (4 mg/5 mL).

Dr. Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:

Zometa® is a registered trademark of Novartis AG

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at kedaru@drreddys.com/ +91-40-66834297
Saunak Savla at saunaks@drreddys.com/ +91-40-49002135
Milan Kalawadia (USA) at mkalawadia@drreddys.com/ +1 908-203-4931

S Rajan at rajans@drreddys.com/ +91-40-49002445

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
08/08 DR REDDY LABORATORIES : Gets nod to export 15 drugs to eu
08/05 Dr reddy's completes buy of teva's portfolio of 8 drugs
08/04 Dr Reddy's completes acquisition of 8 ANDAs from Teva Pharma
08/03 DR REDDY LABORATORIES : . Reddy’s Completes Acquisition of Product Portfol..
08/02 CIPLA : appoints Kedar Upadhye as Global Chief Financial Officer
07/30 Indian drug-makers to acquire teva's products
07/28 DR REDDY LABORATORIES : Pins hopes on new molecules to invigorate profits
07/28 DR REDDY LABORATORIES : Drl eyes complex generics
07/27 DR REDDY LABORATORIES : Lab 10% down on poor Q1 numbers
07/27 DR REDDY LABORATORIES : Reddys Lab ops 9.5% after poor Q1 numbers
More news
Sector news : Pharmaceuticals - NEC
11:34aDJPFIZER : Buys Part of AstraZeneca's Antibiotics Business -- 2nd Update
10:32aDJASTRAZENECA : Sells Part of its Antibiotics Business to Pfizer -- Update
10:15aDJPfizer Buys Part of AstraZeneca's Antibiotics Business
09:03aDJASTRAZENECA : Sells Part of Antibiotics Business to Pfizer for Up to $1.575 Bill..
08/23DJU.S. Lawmakers Plan Hearing Over Wave of Agriculture Mergers
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/27 DR. REDDY'S : Continues To Stumble. Longer-Term Thesis Intact
07/27 Dr. Reddy's Laboratories' (RDY) Q2 2016 Results - Earnings Call Transcript
07/26 Midday Gainers / Losers
07/26 Dr.Reddy's Laboratories revenues off 14% in FQ1
Financials ( INR)
Sales 2017 150 868 M
EBIT 2017 20 257 M
Net income 2017 18 205 M
Debt 2017 7 190 M
Yield 2017 0,63%
P/E ratio 2017 27,96
P/E ratio 2018 20,01
EV / Sales 2017 3,45x
EV / Sales 2018 3,00x
Capitalization 513 693 M
More Financials
Duration : Period :
Dr.Reddy's Laboratories Lt Technical Analysis Chart | DRREDDY | INE089A01023 | 4-Traders
Full-screen chart
Technical analysis trends DR.REDDY'S LABORA...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 46
Average target price 3 150  INR
Spread / Average Target 4,7%
Consensus details
EPS Revisions
More Estimates Revisions
Gunupati Venkateswara Prasad Co-Chairman, Chief Executive Officer & MD
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Abhijit Mukherjee Chief Operating Officer
Kalpana Jaisingh Morparia Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON16.28%326 773
ROCHE HOLDING LTD.-12.26%219 257
NOVARTIS AG-9.97%214 603
PFIZER INC.8.71%212 844
MERCK & CO., INC.20.37%175 812
More Results